Literature DB >> 27188699

A Treatment Approach to Catamenial Epilepsy.

Allison Navis1, Cynthia Harden2.   

Abstract

OPINION STATEMENT: The cyclic hormonal underpinnings of catamenial seizure exacerbations are consistent with the neurophysiologic activity of estrogen and progesterone. For women with catamenial epilepsy who have regular menses, intermittent treatment approaches may be utilized. These interventions are targeted at adding or increasing anti-seizure treatments during established vulnerable days of the menstrual cycle, such as perimenstrually (C1 pattern), at ovulation (C2 pattern), and during the luteal phase (C3 pattern). The single large study of natural progesterone treatment showed benefit for women with clear perimenstrual seizure exacerbations (C1 pattern), but not for subjects with other catamenial patterns or for randomized women with epilepsy of reproductive age who did not have catamenial seizure exacerbations. In this protocol, natural progesterone was given at a high dose during the luteal phase and was generally well tolerated. Other intermittent cyclic treatments include benzodiazepine use, increasing the dose of an anti-seizure drug already in use, or acetazolamide. For women with irregular menses, or those in which the intermittent cyclic treatments are not effective, pharmacologically stopping the menstrual cycle altogether by using synthetic hormones such as medroxyprogesterone (Depo-Provera) or sustained oral contraceptives may be considered.

Entities:  

Keywords:  Acetazolamide; Catamenial epilepsy; Medroxyprogesterone acetate; Neurosteroid; Progesterone

Year:  2016        PMID: 27188699     DOI: 10.1007/s11940-016-0413-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  25 in total

1.  Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial.

Authors:  A G Herzog; K M Fowler; S D Smithson; L A Kalayjian; C N Heck; M R Sperling; J D Liporace; C L Harden; B A Dworetzky; P B Pennell; J M Massaro
Journal:  Neurology       Date:  2012-05-30       Impact factor: 9.910

2.  Luteal-phase defect: the role of Georgeanna Seegar Jones.

Authors:  Howard W Jones
Journal:  Fertil Steril       Date:  2007-11-19       Impact factor: 7.329

3.  Seizure exacerbation associated with inhibition of progesterone metabolism.

Authors:  Andrew G Herzog; Cheryl A Frye
Journal:  Ann Neurol       Date:  2003-03       Impact factor: 10.422

4.  Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants.

Authors:  M Feely; R Calvert; J Gibson
Journal:  Lancet       Date:  1982-07-10       Impact factor: 79.321

5.  Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders.

Authors:  A G Herzog
Journal:  Neurology       Date:  1986-12       Impact factor: 9.910

6.  Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus.

Authors:  A H Gazzaley; N G Weiland; B S McEwen; J H Morrison
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

Review 7.  Catamenial epilepsy: definition, prevalence pathophysiology and treatment.

Authors:  Andrew G Herzog
Journal:  Seizure       Date:  2008-03       Impact factor: 3.184

8.  The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients.

Authors:  J Bauer; L Wildt; D Flügel; H Stefan
Journal:  J Neurol       Date:  1992-05       Impact factor: 4.849

9.  Estrogen administration increases neuronal responses to excitatory amino acids as a long-term effect.

Authors:  S S Smith
Journal:  Brain Res       Date:  1989-12-04       Impact factor: 3.252

10.  Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy.

Authors:  Andrew G Herzog; Cheryl A Frye
Journal:  Neurology       Date:  2014-06-18       Impact factor: 9.910

View more
  5 in total

Review 1.  A Clinical Approach to Catamenial Epilepsy: A Review.

Authors:  Samuel Frank; Nichole A Tyson
Journal:  Perm J       Date:  2020-12

Review 2.  Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.

Authors:  Doodipala Samba Reddy
Journal:  J Neuroendocrinol       Date:  2021-09-10       Impact factor: 3.870

3.  Seizure pathways change on circadian and slower timescales in individual patients with focal epilepsy.

Authors:  Gabrielle M Schroeder; Beate Diehl; Fahmida A Chowdhury; John S Duncan; Jane de Tisi; Andrew J Trevelyan; Rob Forsyth; Andrew Jackson; Peter N Taylor; Yujiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-04       Impact factor: 11.205

4.  WGCNA combined with GSVA to explore biomarkers of refractory neocortical epilepsy.

Authors:  Rui Zhang; Yan Chen; Jia He; Hai-Yan Gou; Yu-Lan Zhu; Yan-Mei Zhu
Journal:  IBRO Neurosci Rep       Date:  2022-10-03

Review 5.  Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis.

Authors:  Doodipala Samba Reddy; Wesley Thompson; Gianmarco Calderara
Journal:  Neurosci Lett       Date:  2021-02-18       Impact factor: 3.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.